OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.

OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings

OPKO Health, Inc. (NASDAQ:OPK ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call.

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.

OPKO Health (OPK) Q3 Earnings Surpass Estimates

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies

WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS).

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

NextPlat Corp

Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GROVE, Fla. and MIAMI , Oct. 7, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-commerce provider, today announced a significant expansion of its exclusive e-commerce distribution agreement with OPKO Health, Inc. (NASDAQ: OPK) ("OPKO") for the online sales of its OPKO Health Europe products in China including securing a new four-year extension and approval to exclusively market its products in Japan.

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

Entera Bio Ltd

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data

Labcorp Holdings Inc

Enhances Labcorp's laboratory services network and expands access to its clinical services  BURLINGTON, N.C. and MIAMI , Sept.

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.03 per share a year ago.

OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates

MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers.

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO's profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency.

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6th at 10:30 a.m. Eastern time.

OPKO Health to Participate in the Jefferies Global Healthcare Conference

Corvus Pharmaceuticals

Intrusion

One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is.

The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK ) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhouni - President and Vice Chairman Adam Logal - SVP and CFO Charles Bishop - CEO, OPKO Renal Gary Nabel - Chief Innovation Officer Yvonne Briggs - LHA IR Conference Call Participants Maury Raycroft - Jefferies Jeff Cohen - Ladenburg Thalmann Company Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Michael Petusky - Barrington Research Operator Hello, and welcome to the OPKO Health First Quarter 2024 Financial Results Conference Call.

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

OPKO Health (OPK) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.02 per share a year ago.

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health.

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time.

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.

News for OPKO Health Stock (OPK)